Carbaril

Summary

Carbaril (CHEMBL46917) is an approved small-molecule EC 3.1.1.7 (acetylcholinesterase) inhibitor.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 201.22 Da · C12H11NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL46917
Name	Carbaril
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6129
ChEBI	CHEBI:3390
Molecular formula	C12H11NO2
Molecular weight	201.22
InChIKey	CVXBEEMKQHEXEN-UHFFFAOYSA-N

SMILES: CNC(=O)OC1=CC=CC2=CC=CC=C21

IUPAC name: naphthalen-1-yl N-methylcarbamate

ChEBI definition: A carbamate ester obtained by the formal condensation of 1-naphthol with methylcarbamic acid.

Pharmacological roles (ChEBI): EC 3.1.1.7 (acetylcholinesterase) inhibitor, carbamate insecticide, EC 3.1.1.8 (cholinesterase) inhibitor, acaricide, agrochemical.

Other ChEBI roles (chemical / environmental): plant growth retardant.

Also known as: Carbaril, Carbarilo, Carbaryl, Carylderm, Clinicide, Derbac, Derbac-c, ENT-23969, NSC-27311, Suleo-c, carbaryl, SID17389992

Patent coverage: 11,931 distinct patent families (36,543 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 36,312 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Ferritin light chain, Progesterone receptor, Prostaglandin G/H synthase 1, Lysosomal alpha-glucosidase, Aldehyde dehydrogenase 1A1, Mitogen-activated protein kinase 1, Acetylcholinesterase, 3-hydroxyacyl-CoA dehydrogenase type-2, Acetylcholinesterase.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAPK1	8.89	Potency	1.3	nM	CHEMBL_ACT_4547192
O42275	5.51	IC50	3100	nM	CHEMBL_ACT_888365
PTGS1	5.43	AC50	3711	nM	CHEMBL_ACT_25205881
PTGS1	5.38	AC50	4192	nM	CHEMBL_ACT_25204948
P23795	5.21	IC50	6100	nM	CHEMBL_ACT_12556720

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).